On this page, you can update your details, access training courses, and find other helpful resources to support your business membership of Anaphylaxis UK.
Since our rebranding and new website in July 2022, we’ve already reached a staggering number of page views.
Our latest social media campaign reached over 650,000 unique people in 10 weeks with nearly 12,000 views on the campaign page and nearly 2,000 sign-ups to the campaign email.
Our Facebook page reaches 489,000 people and our organic post reach is over 72,500.
Our monthly newsletter has an open rate of over 56%.
Download the Anaphylaxis UK Business Member logos along with the Brand Guidelines. Please use the Brand Guidelines on how to correctly display the logos and link to the Anaphylaxis Homepage: https://www.anaphylaxis.org.uk/
The Anaphylaxis UK Business Member logos
The Anaphylaxis UK Brand Guidelines
Access training for you and colleagues here. The training courses are only available to Business Members.
Get the latest news. To feature news of your own, get in touch!
We are delighted to be launching our Bee and Wasp Venom Awareness Campaign for 2024, supported by an educational grant from ALK. The campaign will offer invaluable guidance on bee and wasp sting avoidance, recognising anaphylaxis symptoms, the steps to take in an emergency and information about venom immunotherapy.
Anaphylaxis UK is proud to be recognising our 30th anniversary this year… Three decades of unwavering support. To mark the anniversary, we’re launching our ’30 Reasons’ anniversary campaign to showcase the people and stories that motivate us to do what we do here at Anaphylaxis UK.
Sonia Bagga, 39, went into anaphylactic shock after eating two bites of a chicken wrap that she didn’t know contained sesame seeds while on-board a BA flight returning home in September from a family holiday in Dubai. A doctor on
This project has been set up to provide a step-change in our understanding of food allergy in adulthood by determining its prevalence in the adult population.
The Anaphylaxis Campaign is delighted to hear about the success of Aimmune Therapeutics, Inc. Phase 3 PALISADE trial and publication of its results in the New England Journal of Medicine. PALISADE (Peanut Allergy oral Immunotherapy Study of AR101 for Desensitization, is an international, randomized (3:1),
Some of our Business Members are featured here.
Update your subscription details
Go nowUpdate your company details and logo
Go nowPlease complete the details below so we can set up your new account.